Ironwood Pharmaceuticals (NASDAQ:IRWD) was downgraded by equities research analysts at Mizuho from a “buy” rating to a “neutral” rating in a research note issued on Wednesday. They presently have a $16.00 price target on the biotechnology company’s stock. Mizuho’s price target suggests a potential upside of 1.27% from the stock’s previous close.

Several other research firms have also weighed in on IRWD. Morgan Stanley reissued a “hold” rating on shares of Ironwood Pharmaceuticals in a research note on Monday. Cowen set a $20.00 target price on Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 21st. ValuEngine raised Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub raised Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Finally, Credit Suisse Group started coverage on Ironwood Pharmaceuticals in a research report on Monday, November 27th. They issued a “buy” rating and a $19.00 target price for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the stock. Ironwood Pharmaceuticals currently has an average rating of “Hold” and an average target price of $17.88.

Shares of Ironwood Pharmaceuticals (NASDAQ IRWD) opened at $15.80 on Wednesday. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87. Ironwood Pharmaceuticals has a one year low of $13.43 and a one year high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.07. The business had revenue of $86.80 million during the quarter, compared to analyst estimates of $73.59 million. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The company’s revenue was up 31.3% compared to the same quarter last year. During the same period last year, the company posted ($0.18) EPS. sell-side analysts anticipate that Ironwood Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the stock. Teacher Retirement System of Texas purchased a new stake in shares of Ironwood Pharmaceuticals during the second quarter worth $192,000. Gerber Kawasaki Wealth & Investment Management bought a new position in Ironwood Pharmaceuticals during the third quarter valued at about $170,000. Strs Ohio raised its holdings in Ironwood Pharmaceuticals by 63.1% during the second quarter. Strs Ohio now owns 10,600 shares of the biotechnology company’s stock valued at $200,000 after buying an additional 4,100 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in Ironwood Pharmaceuticals by 5.8% during the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 648 shares in the last quarter. Finally, Aperio Group LLC raised its holdings in Ironwood Pharmaceuticals by 11.9% during the second quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock valued at $249,000 after buying an additional 1,410 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/06/mizuho-downgrades-ironwood-pharmaceuticals-irwd-to-neutral.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.